Harrison, C., Gupta, V., Yacoub, A., Fazal, S., Miller, C., Verstovsek, S., … Talpaz, M. (2021). Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib. In BRITISH JOURNAL OF HAEMATOLOGY (Vol. 193, pp. 110–111).

Harrison, Claire, Vikas Gupta, Abdulraheem Yacoub, Salman Fazal, Carole Miller, Srdan Verstovsek, Ruben Mesa, et al. “Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib.” In BRITISH JOURNAL OF HAEMATOLOGY, 193:110–11, 2021.

Harrison C, Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, et al. Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib. In: BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 110–1.

Harrison, Claire, et al. “Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib.” BRITISH JOURNAL OF HAEMATOLOGY, vol. 193, 2021, pp. 110–11.

Harrison C, Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, Mesa R, Barosi G, Kiladjian J-J, Mattison R, Rein L, Reeves B, Oh S, Parameswaran V, Deeg HJ, Rose S, Chia V, Wang T, Talpaz M. Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib. BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 110–111.